• Michael KaedingEmail author
  • Julia Schmälter
  • Christoph Klika
Open Access


In this chapter, the fundamentals of pharmacovigilance are outlined with a particular emphasis on the role of healthcare professionals in reporting adverse drug reactions (ADRs). It also explains why pharmacovigilance is specifically important regarding biological medicinal products (biologicals).


Healthcare Professional Spontaneous Reporting Marketing Authorisation Causality Assessment Batch Number 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Belton, K. J. and the European Pharmacovigilance Group (1997). Attitude Survey of Adverse Drug-Reaction Reporting by Health Care Professionals across the European Union. European Journal of Pharmacology 52: 423-427.Google Scholar
  2. Alvarez-Requejo, A., Carvajal, A., Bégaud, B., Moride, Y., Vega, T., Martín Arias, L.H. (1998). Under-Reporting of Adverse Drug Reactions: Estimate Based on a Spontaneous Reporting Scheme and a Sentinel System. European Journal of Clinical Pharmacology 54: 483-488.Google Scholar
  3. Arnaiz, J. A., Carné, X., Riba, N., Codina, C., Ribas, J., Trilla, A. (2001). The Use of Evidence in Pharmacovigilance – Case Reports as the Reference Source for Drug Withdrawals. European Journal of Clinical Pharmacology 57: 89-91.Google Scholar
  4. Calvo, B., Zuňiga, L. (2014). EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars. Drug Safety 37: 9-18.Google Scholar
  5. Ebbers, H. C., Mantel-Teeuwisse, A. K., Moors, E. H. M., Schellekens, H., Leufkens, H. C. (2011). Today’s Challenges in Pharmacovigilance: What Can We Learn from Epoetins? Drug Safety 34(4): 273-287.Google Scholar
  6. Eichler, H. G., Pignatti, F., Flamion, B., Leufkens, H., Breckenrige, A. (2008). Balancing Early Market Access to New Drugs with the Need for Benefit/Risk Data: A Mounting Dilemma. Nature Reviews Drug Discovery 7: 818-826.Google Scholar
  7. Giezen, T. J., Straus, S. M. J. M. (2012). Pharmacovigilance of Biosimilars: Challenges and Possible Solutions. Generics and Biosimilars Initiative Journal 1 (3-4): 118-119.Google Scholar
  8. Inácio, P., Airaksinen, M., Cavaco, A. (2015). Language Does Not Come “in Boxes”: Assessing Discrepancies between Adverse Drug Reactions Spontaneous Reporting and MedDRA ® Codes in European Portuguese. Research in Social and Administrative Pharmacy 11: 664-674.Google Scholar
  9. Johnson, C.L., Hutchinson, J. A. (2015). Pharmacovigilance in Europe. Transplantation 99(8): 1542-1543.Google Scholar
  10. Klein, K., Scholl, J. H. G., Vermeer, N. S., Broekmans, A. W., Van Puijenbroek, E. P., De Bruin, M. L., Stolk, P. (2016). Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports. Drug Safety 39: 185-192.Google Scholar
  11. Kumar, A., Khan, H. (2015). Signal Detection and Their Assessment. In Pharmacovigilance. Open Pharmaceutical Science Journal 3: 66-73.Google Scholar
  12. Pal, S. N., Duncombe, C., Falzon, D., Olsson, S. (2013). WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems. Drug Safety 36: 75-81Google Scholar
  13. Vermeer, N. S., Straus, S. M. J. M., Mantel-Teeuwisse, A. K., Domergue, F., Egberts, T. C. G., Leufkens, H. G. M., De Bruin, M. L. (2013). Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases. Drug Safety 36: 617-625.Google Scholar
  14. WHO (2004). Pharmacovigilance: Ensuring the Safe Use of Medicines. WHO Policy Perspectives on Medicines 9.Google Scholar
  15. WHO (2016). WHO Education Guidelines. Last accessed 26.11.2016:

Copyright information

© The Author(s) 2017

Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

Authors and Affiliations

  • Michael Kaeding
    • 1
    Email author
  • Julia Schmälter
    • 1
  • Christoph Klika
    • 1
  1. 1.Institut für PolitikwissenschaftUniversität Duisburg-Essen Institut für PolitikwissenschaftDuisburgGermany

Personalised recommendations